HempNewsBreaks – SinglePoint Inc. (SING) Leverages Rising Popularity of 1606 Hemp Cigarettes

SinglePoint (OTCQB: SING) recently announced plans to expand the launch of its 1606 Hemp cigarettes with a new six-pack countertop display (http://cnw.fm/9dOOJ). An article discussing the company’s new hemp initiatives reads, “‘The great thing about the hemp cigarette is, unlike tobacco, the hemp product can sit up on the counter,’ commented Lambrecht in the interview. Made from broad-spectrum, American-grown, harvested and cured hemp flower, the filtered pre-rolls are made with less than 0.3% THC and contain nearly 20% CBD in each pre-roll, providing a smooth alternative to tobacco products. With a fast-growing fan base of loyal users, the pre-rolls have seen a sales growth rate of 133% this quarter over the previous quarter along with a 233% growth in sales when compared with the same point last month. . . . ‘I was in that business for 30 years and actually took a cigar distribution company public on the Nasdaq,’ explained Lambrecht. ‘We’re really excited about this box that we developed because this box is going to be able to sit right up at the counter. We’re going to be sending that out to our extensive store list, so I think in the upcoming weeks I’m hopefully going to really have some big results on some sales from some big chains and distributors that are going to take this product on.’”

To view the full article, visit http://cnw.fm/mpNi6

About SinglePoint Inc.

Founded in 2011, SinglePoint invests in and acquires brands and companies that will benefit from injection of growth capital and the company’s sales and marketing expertise. SING’s portfolio currently includes solar, hemp and technology applications. SinglePoint is working to grow the company to a multinational brand. For more information, visit the company’s website at www.SinglePoint.com.

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://cnw.fm/SING

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer

Do you have questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.HempWire.com
303.498.7722 Office
Editor@HempWire.net

HempWire is part of the InvestorBrandNetwork.

420 with CNW – There’s No Link Between Marijuana Use and Increased Stroke Risk, Study Finds

As more states legalize marijuana and its use becomes more prevalent, there have been numerous studies about its potential risks and benefits. In particular, there have been a number of conflicting results regarding marijuana use and increased stroke risk, with some studies stating that it reduces the risk while others argue that it exponentially increases the risk. According to a recent study by a team of neurologists at the University of Mississippi Medical Center, there is no link between increased stroke risk and marijuana use.

The team analyzed data from nearly 10,000 individuals and they found that cannabis use does not increase your risk of having a stroke. “Previous studies that investigated cannabis use and risk of stroke have had conflicting results, some showing a decreased risk and others showing a greatly increased risk,” says Carmela San Luis, MD, lead investigator and a member of the American Academy of Neurology (“AAN”).

“Our observational study looked specifically at recent cannabis use by reviewing drug testing data for people admitted to the hospital. While more research is needed with larger numbers of people, our study lends support to the studies showing that cannabis use does not increase the risk of stroke.” San Luis and a team of colleagues from the University of Mississippi in Jackson designed the study to assess potential correlations between marijuana use (a positive cannabinoid urine drug screen on admission) and a diagnosis of an acute ischemic stroke.

They studied de-identified data from 9,350 patients who were 18 years old and over admitted in the University of Mississippi Medical Center from 2015 -2017, and only 18% of the patients tested positive for cannabis use. Ischemic stroke was observed in 7.91% (130) of the 1,643 individuals who tested positive for cannabis and in 15.66% (1207) of those who tested negative. The database also granted the researchers access to information related to age, ethnicity, sickle cell disease, family history of stroke, hypertension status, obesity, diabetes mellitus, cigarette smoking, atrial fibrillation, carotid artery stenosis and other cardiac conditions. They were included as confounders in the researchers’ multivariate logistic regression analysis.

San Luis notes that the study only captured whether people had used marijuana recently and that it did not collect information on how much marijuana was consumed or any other information about their history of prior use.

“Our research adds to the list of studies with conflicting results, so it’s important to continue to investigate stroke risk and cannabis use. Future studies are now needed in larger groups of people that not only include data from drug screenings but also from dosing amounts and a person’s history of cannabis use.”

Industry watchers say the findings of such studies are of interest to sector players like SinglePoint, Inc. (OTCQB: SING) since the industry would greatly benefit once reliable third-party information is widely available on the various myths and misconceptions circulating about marijuana.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Why Some People May Not See Results After Consuming CBD

Over the past few years, cannabidiol (“CBD”) has gained the reputation of a cure all, and marketers have leaned quite heavily into it. Plenty of companies that process and sell CBD have taken to making all kinds of medical claims to attract customers. However, the truth of the matter is that a large portion of the evidence backing CBD’s medical abilities is anecdotal, and the cannabis extract definitely won’t fix all your health issues.

It has become immensely popular in recent years, with CBD gummies being the third most searched for food in 2018. What a lot of marketing campaigns fail to say is that for the most part, CBD reacts with different people in different ways, and another person’s experience with CBD will not exactly mirror your own. So why do some people fail to see tangible results after consuming CBD?

For starters, CBD reacts with the endocannabinoid system (“ECS”), a peripheral nervous system in charge of maintaining the homeostasis or internal balance of the body. It is made up of individual cannabinoid receptors spread throughout the body, and everyone’s ECS is unique in both its make up and level of functionality. Like a fingerprint, no two are alike, so everyone’s reaction will be slightly different based on their ECS.

While smoking or vaping cannabis has a more or less instantaneous effect, CBD can take a while, depending on the method of application. Topicals will offer quick results but if you’re ingesting your CBD, it may take you weeks of daily consistent use for the effects to kick in. A lot of the time, new users will approach it with an ‘instant gratification’ mindset, and seeing no results after a few doses, drop too soon.

Additionally, you may just be using the wrong product. Despite being only a few years old, the CBD space is filled with a huge variety of products. In broad terms, there are the full-spectrum products, which contain a host of other cannabinoids and terpenes, and there are the isolates, where all the other chemicals are stripped away to leave only CBD. Full-spectrum products are more popular as the sum of all the cannabinoids and terpenes work together in a complementary way in what has been termed the ‘entourage effect.’

Like most medicines, CBD doesn’t work in a vacuum, and you will have to put in effort for it to be effective. Eat healthy, exercise regularly, get plenty of sleep, and consistent CBD use will supplement your healthy lifestyle.

The variation in the way different people respond to CBD may be the reason why industry actors like Round Meadow Holdings Corp. and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) encourage customers to read all the available literature before choosing a CBD product to buy.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Announces Retirement of CFO, Names Successor

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp branded products company in the U.S., today announced that its Chief Financial Officer, Jon Paul, will be retiring at the end of this month. According to the update, current Vice President of Finance, Nate Pearson, has been identified as his successor, while Paul, following his retirement, will continue in an advisory role to ensure a smooth transition. “Jon has played an integral role in our organization since the day he joined,” Jake Heimark, co-founder and CEO of Plus Products, stated in the news release. “The financial and regulatory environments in our industry remain extraordinarily complex, and Jon has built the infrastructure and relationships that we believe will enable PLUS to succeed for years to come. It has been a pleasure to work with him for the past few years, and I am grateful he will continue working closely with the company moving forward.”

To view the full press release, visit http://cnw.fm/De0db

About PLUS

PLUS is a hemp and cannabis food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable – that begins with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, CA. For more information, visit the company’s website at www.PlusProducts.com.

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://cnw.fm/PLUS

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Federal Financial Regulator Says Marijuana Banking is a Difficult Issue

Despite being federally prohibited, the state-legal marijuana industry has been growing steadily for the past few years. Things haven’t been rosy for the often controversial sector, and the fact that marijuana is illegal at the federal level has made it challenging for businesses to operate. Admittedly, the biggest hurdle that the industry has faced is lack of access to banking.

Fearing legal retaliation from the federal government, most banking institutions avoid marijuana businesses, locking them out of accessing credit or loans and forcing them to operate on a cash-only basis. There have been numerous calls from stakeholders and advocates to rectify this situation, but according to the head of the Federal Deposit Insurance Corporation (“FDIC”), marijuana banking represents the ‘most challenging issue’ she has encountered at the agency.

“At a federal level it is still an illegal substance, and at many state levels, it’s now legal, and it’s legal to frankly bank it at a state level. And so banks find themselves caught between the federal regulatory regime and the state,” says FDIC Chair Jelena McWilliams. While there are hopes that Congress will pass a bill that gives the marijuana sector access to banking services, she tells banks that “there’s so much uncertainty in this space that as a federal regulator, I still have to say it’s illegal to bank marijuana.”

“We know we have banks that are banking marijuana businesses, and you know, we can’t bless them and say ‘go ahead and do it.’ But to the extent you’re doing it because it’s legal in your state, follow FinCEN guidance,” she says, referring to guidance issued for financial services that bank marijuana businesses by the Financial Crimes Enforcement Network (FinCEN) in 2014.

Stakeholders and advocates have been holding out hope that the historic Secure and Fair Enforcement (“SAFE”) Banking Act could still advance in Congress this year Sponsored by Rep. Ed Perlmutter, the bill would protect banks and financial institutions that serviced the marijuana industry from being penalized by federal regulators. The need for cashless transactions has been made even more urgent by the ongoing coronavirus crisis. Not only does having piles of cash around pose a security risk, but it increases the staff’s and customers’ chances of being infected by the virus.

This resulted in the inclusion of language from the SAFE Banking Act into a House-passed coronavirus relief package. It is now waiting for Congressional approval.

Industry watchers believe that sector players like Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) may be wondering about what sort of extreme event will cause the federal government to finally allow banks to serve legal marijuana businesses in nearly all the states in the country.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Uruguay Sends Another Huge Consignment of Marijuana to Europe

Last month, Uruguay-based Fotmer Life Sciences exported a large shipment of medical cannabis to Portugal. This came about six months after Fortmer shipped one metric ton of high-THC cannabis flower to the same country. The 2019 shipment of high-THC flower was believed to have been the largest ever amount of cannabis flower exported in a single shipment, but weighing in at 3,133 pounds, the May shipment takes the cake.

According to Uruguayan documents dated May 19, 2020, the declared customs value of the latest shipment was about $2 per gram, including costs, insurance and freight. Although no company has publicly taken responsibility for importing the shipments into Europe, it could spur other European importers to follow suit and turn to Portugal for high-THC cannabis. Fortmer Life Sciences has exported roughly 6,613 pounds of cannabis flower since last October, making Uruguay one of the few countries exporting large quantities of the product.

Netherlands is undeniably the one of biggest exporters of cannabis flower in the world, having exported a total of 9700 pounds of cannabis in 2019. However, unlike the shipments from Uruguay, the Dutch exports were processed in a European Union-Good Manufacturing Practice (EU-GMP)-certified facility. According to Fortmer CEO Jordan Lewis, the company produces in facilities certified with Good Agricultural and Collection Practice (“GCAP”) and Uruguayan-GMP certification.

“As has been demonstrated by Fortmer as well as other companies, the pathway for GCAP product as an input into an EU-GMP supply chain is both viable and cost effective,’ he says, adding that the firm has the ‘near-term goal of achieving EU-GMP certification.’ He says that he cannot comment on the identity of the European buyer, but whoever they are, they are effectively paving the way for other medical cannabis companies to export into Europe without first obtaining EU-GMP certification.

It goes without saying that the cannabis has to be grown and harvested under certain quality standards and processed in an EU-GMP facility in Europe, of course. “We are OK with the large public companies competing at the point of sale through branding initiatives while we provide private label and contract cultivation solutions to those myriad competitors,” Lewis says.

It would not be the first time non EU-GMP flower exported from Uruguay is being used to manufacture extracts for medical use in an EU-GMP facility. As Karina Lahnakoski, partner in Rick Advisory at CCI Deloitte in Canada says, “the application of GACP versus EU-GMP, and where in the process GACP transitions to GMP, is a subject that is still debated in industry.”

“A full understanding of the supply chain and the jurisdictional requirements is required to apply the right quality controls.”

Analysts say industry actors like The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) are glad that the cannabis industry has grown to the level where intercontinental trade in the plant matter is now possible as shown by the Uruguayan exports.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Engages Toronto-based Dalriada to Advance NCE IP Portfolio

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced its selection of Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. According to the update, Dalriada, a leading contract research organization (“CRO”) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms. “It is with great pleasure that we welcome the Dalriada group to Champignon,” Champignon Special Advisor Dr Joseph Gabriele stated in the news release. “Dalriada’s expertise in medicinal chemistry will be a monumental addition to Champignon’s innovative diverse formulation platforms by their expertise in the synthesis of molecules, including existing psychedelics (ketamine, psilocybin and MDMA), as well as novel new psychedelic-like molecules. This synergistic collaboration will differentiate Champignon from other companies in the psychedelic space by boosting our ability to maintain an inhouse infrastructure for the clinical delivery NCEs.”

To view the full press release, visit http://cnw.fm/6KpoK

About Champignon Brands Inc.

Champignon Brands (CSE: SHRM) is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com

905.674.5977

Office
Editor@CanadianCannabisWire.com

420 with CNW – The White House is Reviewing FDA Research Guidelines on Marijuana and CBD

For the past year or so, the U.S. Food and Drug Administration (“FDA”) has been under mounting pressure from advocates and stakeholders to create a comprehensive regulatory plan for the growing CBD industry. Although the nascent industry is already worth millions in sales and filled with tons of sellers, it is barely regulated. Not only has this made it difficult for businesses to operate, but it has called into question the efficacy and safety of the products being sold.

Last week, the agency submitted a draft of a federal plan for marijuana and CBD research titled ‘Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research’ to the White House Office of Management and Budget (“OMB”). Although details on the contents of the document are sparse, an FDA spokesman indicated that it is related to the agency’s ongoing work to develop broader CBD regulations. These regulations would eventually allow for the marketing of cannabis products as dietary supplements or food items.

“We recognize that there is substantial public interest in marketing and accessing CBD for a variety of products. We are working toward a goal of providing additional guidance, and have made substantial progress. There are many questions to explore regarding the science, safety, effectiveness, and quality of products containing CBD, and we need to do our due diligence,” said the FDA in a statement.

“As part of our work, the FDA continues to explore potential pathways for various types of CBD products to be lawfully marketed. An important component of this work is obtaining and evaluating information to address outstanding questions related to the safety of CBD products that will inform our consideration of potential regulatory frameworks for CBD while maintaining the FDA’s rigorous public health standards.”

Stakeholders will now have to wait and see if the FDA will wait for the guidance to be finalized by the OMB and for the required research to be completed before crafting a regulatory structure for the industry.

However, according to former FDA Commissioner Scott Gottlieb, White House policies requiring OMB to review scientific documents in the first place is an erroneous step that delays the issuance of guidance. “OMB new policies have led to the unprecedented review of FDA’s technical and scientific guidelines, documents in development and review for two years, including on clinical research on prescription cannabis compounds and endorphins for studies of opioid use disorder,” he says.

The FDA, on the other hand, says that it “will continue to update the public about our path forward as our work progresses, and provide information that is based in sound science and data.”

Industry watchers say the cannabis industry, including entities like SinglePoint, Inc. (OTCQB: SING), is hoping that the FDA will not release research guidelines that make it almost impossible to perform any meaningful research.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Maine Sued for Giving Non-Residents Access to its Marijuana Market

The state of Maine is being sued by local marijuana businesses for refusing to enforce a component of its marijuana laws. On Friday, the Maine Cannabis Coalition filed a lawsuit against the state, claiming that the Department of Administrative and Financial Services was in violation of state law after it failed to enforce the residency requirements included by lawmakers in the Marijuana Legalization Act.

According to the law, only Maine residents can run a recreational marijuana grow, manufacturing, or retail operation. Last month, the state announced that it would abandon the residency requirement, a move that garnered outrage from stakeholders and local marijuana businesses.

“Maine Cannabis Coalition and its members along with many other citizens fought hard for two years to include residency. To have it all be ignored after all the hard work and efforts is extremely aggravating to the citizens and policymakers of Maine who expect no one to be above the law,” said the coalition in a statement.

The announcement was made after Wellness Connection of Maine filed a lawsuit against the state seeking to overturn the residency requirement. The Auburn-based company operates four of the state’s medical marijuana dispensaries, and it has financial ties to international cannabis company Acreage Holdings. It claimed that the rule is unconstitutional and makes it harder for companies seeking to operate recreational marijuana to raise money.

Maine Cannabis Coalition argues that the state’s decision to grant non-residents licenses hurts medical marijuana providers by increasing the number of rivals competing for limited market share. Dawson Julia, the co-founder of the Maine Cannabis Coalition and Christian Roney of Waterville, who is seeking a recreational marijuana business license, say they relied on the competitive advantage offered by the Maine residency requirement when developing their business plans.

They want the Office of Marijuana Policy to follow through and enforce the residency requirement when awarding recreational marijuana business licenses. According to their lawsuit, the office has no authority to abandon a state law that has not been struck down by any court or repealed by the state legislature. It is seeking an injunction barring the Office of Marijuana Policy from awarding licenses to out of state applicants.

“This is a pay-to-play constitutional meltdown scheme being orchestrated by the fat cats of Wall Street,” Julie says.

Erik Gundersen, Director of the Office of Marijuana Policy says that his office took action on the advice of the Attorney General’s Office, which concluded the state would be unable to beat the Wellness Connection of Maine lawsuit.

It would be interesting to hear what industry players like Sugarmade, Inc. (OTCQB: SGMD) think about the legal battle shaping up in Maine even before the recreational pot industry gets underway.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – SinglePoint, Inc. (SING) President Discusses Online Solar Purchasing Platform and 1606 Hemp Expansion on MoneyTV with Donald Baillargeon

SinglePoint (OTCQB: SING) was featured on this week’s episode of MoneyTV with Donald Baillargeon. The internationally syndicated program covers money-focused topics, featuring various companies and in-depth interviews with CEOs and executives that offer insights into operations and future outlooks. MoneyTV is viewed in over 200 million households in more than 75 countries. Among other highlights from this week’s program, SinglePoint President Wil Ralston discussed the company’s implementation of an online purchasing platform to streamline the process for solar customers. The interview also covers expansion of the company’s 1606 Hemp brand, which is now sold in over 400 stores. “We’re continuing to push forward on 1606,” Ralston stated in the interview. “We’ve seen great success from our campaign where we brought in multiple different sales reps who’ve been calling all around the nation and onboarding new accounts.”

To view the full press releases, visit http://cnw.fm/65W0b and http://cnw.fm/1vPtG

About SinglePoint, Inc.

Founded in 2011, SinglePoint, Inc. invests in and acquires brands and companies that will benefit from injection of growth capital and its sales and marketing expertise. The company’s portfolio currently includes solar, hemp and technology applications. SinglePoint is working to grow the company to a multi-national brand. For more information, visit the company’s website at www.SinglePoint.com.

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://cnw.fm/SING

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com

303.498.7722

Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.